-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GPVG/YodQXA6sxTR/sYgMrfXedm5LNoJRd7lcxLLBhYpMjw14Zu5/+pqLeOwRibk jpYVM3NhEHQhI36BbajIJg== 0001193125-10-245205.txt : 20101103 0001193125-10-245205.hdr.sgml : 20101103 20101103061155 ACCESSION NUMBER: 0001193125-10-245205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20101103 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20101103 DATE AS OF CHANGE: 20101103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WELLPOINT, INC CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 101159907 BUSINESS ADDRESS: STREET 1: 120 MONUMENT CIRCLE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 3174886000 MAIL ADDRESS: STREET 1: 120 MONUMENT CIRCLE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 FORMER COMPANY: FORMER CONFORMED NAME: ANTHEM INC DATE OF NAME CHANGE: 20010730 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2010

 

 

WELLPOINT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Indiana   001-16751   35-2145715

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

120 Monument Circle

Indianapolis, IN 46204

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (317) 488-6000

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Section 2—Financial Information.

 

Item 2.02 Results of Operations and Financial Condition

On November 3, 2010, WellPoint, Inc. issued a press release reporting its financial results for its third quarter ended September 30, 2010. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

All of the information furnished in this report (including Exhibit 99.1 hereto) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and unless expressly set forth by specific reference in such filings, shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

Section 9—Financial Statements and Exhibits.

 

Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibits.

 

  (c) Exhibits.

The following exhibit is being furnished herewith:

 

Exhibit
No.

  

Exhibit

99.1    Press Release dated November 3, 2010 reporting WellPoint, Inc. financial results for its third quarter ended September 30, 2010.

 

- 2 -


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 3, 2010

 

WELLPOINT, INC.
By:  

/s/ John Cannon

Name:   John Cannon
Title:   EVP, General Counsel and Corporate Secretary

 

- 3 -


 

EXHIBIT INDEX

 

Exhibit
No.

  

Exhibit

99.1    Press Release dated November 3, 2010 reporting WellPoint, Inc. financial results for its third quarter ended September 30, 2010.

 

- 4 -

EX-99.1 2 dex991.htm PRESS RELEASE Press Release

 

Exhibit 99.1

LOGO

WELLPOINT REPORTS THIRD QUARTER 2010 RESULTS

 

   

Net income was $1.84 per share, including net investment gains of $0.10 per share

 

   

Medical enrollment totaled 33.5 million members as of September 30, 2010

 

   

Selling, general and administrative expenses declined by $170 million from the prior year quarter and the SG&A expense ratio declined by 30 basis points to 14.6 percent

 

   

Full year 2010 net income is now expected to be at least $6.60 per share, including net investment gains of $0.18 per share, partially offset by an impairment charge of $0.03 per share

Indianapolis, Ind. – Nov. 3, 2010 – WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2010 net income was $739.1 million, or $1.84 per share, including net investment gains of $37.9 million after-tax, or approximately $0.10 per share. Net income in the third quarter of 2009 was $730.2 million, or $1.53 per share, which included net investment gains of $14.1 million after-tax, or $0.03 per share, and an impairment charge totaling $134.4 million after-tax, or $0.28 per share.

Excluding the items noted above for each period, adjusted net income was $1.74 per share in the third quarter of 2010, compared with adjusted net income of $1.78 per share in the prior-year quarter (refer to page 14 for a reconciliation to the most directly comparable measures calculated in accordance with U.S. generally accepted accounting principles, or “GAAP”).

“We are pleased with our third quarter performance, which exceeded our forecast primarily due to higher than anticipated favorable reserve development and disciplined administrative expense control. Membership was stable in the quarter, and we continued to grow our Blue-branded businesses. Blue-branded Commercial and Individual enrollment increased by 53,000 in the quarter and is up 208,000 on a year-to-date basis, indicating that we continue to provide excellent value for our customers in this difficult economy,” said Angela F. Braly, chair, president and chief executive officer.

“As we prepare for 2011, we are projecting another year of strong growth in the National Accounts business. We are also taking actions to further improve our administrative efficiency and effectiveness, while delivering excellent service and a superior customer experience, which is becoming increasingly important as we continue to position our company for success in the changing marketplace,” added Braly.

“Based on our overall performance, we have increased our year-end 2010 enrollment expectation by 200,000 members, and also raised full-year 2010 guidance for earnings per share to at least $6.60, or at

 

1


least $6.45 on an adjusted basis,” said Wayne S. DeVeydt, executive vice president and chief financial officer. “We also expect to complete more than $4 billion of share repurchases during 2010, representing a significant return of capital to our shareholders following the sale of NextRx at the end of last year.”

CONSOLIDATED HIGHLIGHTS

Membership: Medical enrollment was 33.5 million members at September 30, 2010, a decrease of 382,000 members, or 1.1 percent, from approximately 33.9 million at September 30, 2009. The decline occurred in the Company’s non-Blue business, which experienced a reduction of 590,000 members, primarily due to the strategic transfer of UniCare Individual and Group business in Texas and Illinois to another Blue Cross & Blue Shield plan. The decline in non-Blue enrollment was partially offset by growth of 76,000 members in Blue-branded Commercial and Individual products, an increase of 66,000 members in the Federal Employee Program (“FEP”), and growth of 35,000 and 31,000 members, respectively, in the State Sponsored and Senior businesses.

Medical enrollment was stable in the third quarter of 2010, with membership in Blue-branded Commercial and Individual businesses increasing by 53,000 sequentially, offset by continued attrition in non-Blue business. In total, enrollment declined by 19,000 members, or 0.1 percent, from June 30, 2010. Enrollment in both fully insured and self-funded products at September 30, 2010, was higher than expected, and the Company has raised its year-end 2010 membership expectation to 33.3 million members, primarily due to the stabilizing membership trends in its Commercial Business segment.

Operating Revenue: Operating revenue totaled approximately $14.3 billion in the third quarter of 2010, a decrease of $872.6 million, or 5.7 percent, from $15.2 billion in the third quarter of 2009. The conversion of a large municipal group to a self-funded arrangement during the second quarter of 2010 accounted for more than 40 percent of the decline. The remaining reduction was partially attributable to lower fully insured membership resulting from economic conditions and the transfer of UniCare business in Texas and Illinois. Operating revenue was also lower due to the sale of the NextRx pharmacy benefit management subsidiaries (“NextRx”) in the fourth quarter of 2009.

Benefit Expense Ratio: The benefit expense ratio was 83.8 percent in the third quarter of 2010, an increase of 170 basis points from 82.1 percent in the third quarter of 2009, driven by the Senior and Individual businesses. The Senior benefit expense ratio increased primarily due to the reduction in federal reimbursement rates for the Medicare Advantage program in 2010. The Individual benefit expense ratio increased primarily due to the delay in implementing rate increases in California. The increases in Senior and Individual were partially offset by an improvement in the benefit expense ratio for Local Group business.

During the third quarter of 2010, the Company recognized an estimated $110 million of higher than anticipated favorable reserve development, as compared to $112 million of higher than expected favorable development that was recognized in the same period of 2009.

Medical Cost Trends: Trends represent Local Group fully insured business.

For the full year of 2010, the Company now projects that underlying medical cost trend will be in the range of 7.0 percent, plus or minus 50 basis points. Unit cost increases continue to be the primary driver of overall medical cost trend, while underlying utilization has been lower than expected in 2010.

 

2


 

Days in Claims Payable: Days in Claims Payable (“DCP”) as of September 30, 2010, was 40.7 days, a decrease of 1.4 from 42.1 days as of June 30, 2010. Approximately 0.9 days of the reduction related to the higher-than-anticipated favorable reserve development recognized during the third quarter. The remaining decline was driven by the conversion of large group accounts to self-funding arrangements.

SG&A Expense Ratio: The SG&A expense ratio was 14.6 percent in the third quarter of 2010, a decrease of 30 basis points from 14.9 percent in the third quarter of 2009. The decrease was driven by lower administrative costs, reflecting the fourth quarter 2009 sale of NextRx and the Company’s ongoing efficiency initiatives, partially offset by implementation costs related to health care reform and the decline in operating revenue. Total SG&A expense declined by $170.3 million, or 7.5 percent, relative to the third quarter of 2009.

Operating Cash Flow: Operating cash flow for the first nine months of 2010 totaled $829.7 million, and included $1.2 billion of tax payments related to the fourth quarter 2009 sale of NextRx. Operating cash flow totaled $896.5 million in the third quarter of 2010, or 1.2 times net income.

Share Repurchase Program: During the first nine months of 2010, the Company repurchased 58.9 million shares of its common stock, or 13.1 percent of the shares outstanding at December 31, 2009, for approximately $3.3 billion, following the sale of NextRx. As of September 30, 2010, the Company’s remaining Board-approved share repurchase authorization totaled $538.6 million. The Company expects to utilize this authorization in the fourth quarter of 2010, subject to market and industry conditions.

Investment Portfolio & Capital Position: During the third quarter of 2010, the Company recorded net investment gains of $58.4 million pre-tax, consisting of net realized gains from the sales of securities totaling $61.6 million, partially offset by other than temporary impairments totaling $3.2 million. In the third quarter of 2009, the Company experienced net investment gains of $21.5 million pre-tax, consisting of net realized gains from the sales of securities totaling $52.2 million pre-tax, partially offset by other-than-temporary impairments totaling $30.7 million. As of September 30, 2010, the Company’s net unrealized gain position in the investment portfolio was $1.2 billion, consisting of net unrealized gains on fixed maturity and equity securities totaling $916.6 million and $250.9 million, respectively.

As of September 30, 2010, cash and investments at the parent company totaled approximately $2.9 billion.

 

3


 

REPORTABLE SEGMENTS

WellPoint, Inc. has the following reportable segments: Commercial Business, which includes the Local Group, National, UniCare and Specialty Products lines of business; Consumer Business, which includes the Individual, Senior and State Sponsored lines of business; and Other, which includes Comprehensive Health Solutions (including NextRx for the three and nine months ended September 30, 2009), FEP business, National Government Services, inter-segment sales and expense eliminations, and corporate expenses not allocated to the other reportable segments.

Operating revenue and operating gain are the key measures used by management to evaluate performance in each segment.

WellPoint, Inc.

Reportable Segment Highlights

(Unaudited)

 

      Three Months Ended September 30     Nine Months Ended September 30  
(In millions)    2010     2009     Change     2010     2009     Change  

Operating Revenue

            

Commercial Business

   $ 8,512.1      $ 9,311.0        (8.6 %)    $ 26,104.8      $ 28,018.3        (6.8 %) 

Consumer Business

     4,039.1        4,089.8        (1.2 %)      12,044.2        12,215.7        (1.4 %) 

Other

     1,783.2        1,806.2        (1.3 %)      5,278.6        5,537.5        (4.7 %) 
                                    

Total Operating Revenue

     14,334.4        15,207.0        (5.7 %)      43,427.6        45,771.5        (5.1 %) 

Operating Gain

            

Commercial Business

   $ 760.9      $ 628.0        21.2   $ 2,485.0      $ 2,113.5        17.6

Consumer Business

     261.7        520.0        (49.7 %)      888.6        1,120.8        (20.7 %) 

Other

     17.1        133.2        (87.2 %)      10.8        368.6        (97.1 %) 
                                    

Total Operating Gain

     1,039.7        1,281.2        (18.8 %)      3,384.4        3,602.9        (6.1 %) 

Operating Margin

            

Commercial Business

     8.9     6.7     220 bp      9.5     7.5     200 bp 

Consumer Business

     6.5     12.7     (620 )bp      7.4     9.2     (180 )bp 

Total Operating Margin

     7.3     8.4     (110 )bp      7.8     7.9     (10 )bp 

Commercial Business: Operating gain for the Commercial Business segment was $760.9 million in the third quarter of 2010, an increase of $132.9 million, or 21.2 percent, from $628.0 million in the third quarter of 2009. The increase was driven by operating improvements in the Local Group business and included an estimated $75 million of higher than anticipated favorable reserve development recognized in the current year quarter. Approximately $64.0 million of higher-than-anticipated favorable development was recognized in the Commercial segment during the third quarter of 2009.

Consumer Business: Operating gain for the Consumer Business segment was $261.7 million in the third quarter of 2010, a decrease of $258.3 million, or 49.7 percent, compared with $520.0 million in the third quarter of 2009. The decline in operating gain was driven by lower performance in the Senior and Individual businesses. Results for the Company’s Medicare Advantage products declined as a result of the reduction in federal reimbursement rates and lower risk score settlement revenue in 2010. Individual business performance decreased due to the delay in implementing rate increases in

 

4


California and the recognition of a premium credit to be issued to certain policyholders in Colorado during the fourth quarter of 2010.

During the third quarter of 2010, the Company recognized an estimated $35 million of higher-than-anticipated reserve development in the Consumer segment, compared with approximately $48.0 million of higher-than-anticipated favorable development that was recognized in the prior year quarter.

Other: Operating gain in the Other segment declined by $116.1 million, or 87.2 percent, compared with the third quarter of 2009, due to the sale of NextRx in the fourth quarter of 2009.

OUTLOOK

Full Year 2010:

 

   

Net income is now expected to be at least $6.60 per share, including net investment gains of approximately $0.18 per share recorded during the first three quarters of 2010, partially offset by the first quarter intangible asset impairment charge of $0.03 per share. This outlook includes no net investment gains or losses or asset impairment charges beyond those recorded during the first three quarters of 2010.

 

   

Year-end medical enrollment is now expected to be 33.3 million, consisting of 19.6 million self-funded members and 13.7 million fully insured members.

 

   

Operating revenue is expected to total approximately $58.0 billion.

 

   

The benefit expense ratio is now expected to be approximately 83.7 percent.

 

   

The SG&A expense ratio is now expected to be approximately 14.9 percent.

 

   

Operating cash flow is expected to exceed $1.2 billion, including the unfavorable impact of the $1.2 billion of first quarter tax payments related to the prior year sale of the NextRx subsidiaries.

 

5


 

Basis of Presentation

 

1. Operating gain is defined as operating revenue less benefit expense, selling expense, general and administrative expense, and cost of drugs. Operating gain is used to analyze profit or loss on a segment basis. Consolidated operating gain is a non-GAAP measure.

 

2. Operating margin is defined as operating gain divided by operating revenue. Consolidated operating margin is a non-GAAP measure.

 

3. Certain prior period amounts have been reclassified to conform to the current period presentation.

Conference Call and Webcast

Management will host a conference call and webcast today at 7:30 a.m. Eastern Daylight Time (“EDT”) to discuss its third quarter earnings results and updated outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:

 

888-423-3268 (Domestic)    800-475-6701 (Domestic Replay)
651-291-5254 (International)    320-365-3844 (International Replay)

An access code is not required for today’s conference call. The access code for the replay is 123547. The replay will be available from 11 a.m. EDT today until the end of the day on Nov. 17, 2010. The call will also be available through a live webcast at www.wellpoint.com under “Investor Info.” A webcast replay will be available following the call.

Contacts:

 

Investor Relations    Media
Michael Kleinman, 317-488-6713    Kristin Binns, 917-697-7802

 

6


 

About WellPoint, Inc.

WellPoint works to simplify the connection between Health, Care and Value. We help to improve the health of our communities, deliver better care to members, and provide greater value to our customers and shareholders. WellPoint is the nation’s largest health benefits company, with more than 33 million members in its affiliated health plans, and a total of more than 70 million individuals served through all subsidiaries. As an independent licensee of the Blue Cross and Blue Shield Association, WellPoint serves members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as the Blue Cross Blue Shield licensee in 10 New York City metropolitan and surrounding counties and as the Blue Cross or Blue Cross Blue Shield licensee in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), and Wisconsin. In a majority of these service areas, WellPoint does business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield or Empire Blue Cross Blue Shield (in the New York service areas). WellPoint also serves customers throughout much of the country as UniCare. Additional information about WellPoint is available at www.wellpoint.com.

LOGO

 

7


 

WellPoint, Inc.

Membership Summary

(Unaudited and in Thousands)

 

                          Change from  

Medical Membership

   September 30,
2010
     December 31,
2009
     September 30,
2009
     December 31,
2009
    September 30,
2009
 

Customer Type

             

Local Group

     15,171         15,643         15,717         (3.0 %)      (3.5 %) 

National Accounts

     7,091         6,813         6,857         4.1     3.4

BlueCard

     4,783         4,744         4,779         0.8     0.1
                               

Total National

     11,874         11,557         11,636         2.7     2.0

Individual

     1,967         2,131         2,173         (7.7 %)      (9.5 %) 

Senior

     1,256         1,215         1,225         3.4     2.5

State Sponsored

     1,752         1,733         1,717         1.1     2.0

FEP

     1,453         1,391         1,387         4.5     4.8
                               

Total Medical Membership

     33,473         33,670         33,855         (0.6 %)      (1.1 %) 
                               

Funding Arrangement

             

Self-Funded

     19,650         18,236         18,316         7.8     7.3

Fully-Insured

     13,823         15,434         15,539         (10.4 %)      (11.0 %) 
                               

Total Medical Membership

     33,473         33,670         33,855         (0.6 %)      (1.1 %) 
                               

Reportable Segment

             

Commercial

     27,050         27,356         27,530         (1.1 %)      (1.7 %) 

Consumer

     4,970         4,923         4,938         1.0     0.6

Other

     1,453         1,391         1,387         4.5     4.8
                               

Total Medical Membership

     33,473         33,670         33,855         (0.6 %)      (1.1 %) 
                               

Other Membership

             

Behavioral Health Membership

     23,776         22,965         22,883         3.5     3.9

Life and Disability Membership

     5,152         5,393         5,425         (4.5 %)      (5.0 %) 

Dental Membership

     4,028         4,284         4,322         (6.0 %)      (6.8 %) 

Managed Dental Membership

     4,280         3,949         3,953         8.4     8.3

Vision Membership

     3,475         3,088         3,037         12.5     14.4

Medicare Part D Membership

     1,234         1,509         1,633         (18.2 %)      (24.4 %) 

 

8


 

WellPoint, Inc.

Consolidated Statements of Income

(Unaudited)

 

      Three Months Ended
September 30
       
(In millions, except per share data)    2010     2009     Change  

Revenues

      

Premiums

   $ 13,366.7      $ 14,070.7        (5.0 %) 

Administrative fees

     963.1        969.1        (0.6 %) 

Other revenue

     4.6        167.2        (97.2 %) 
                  

Total operating revenue

     14,334.4        15,207.0        (5.7 %) 

Net investment income

     205.4        196.6        4.5

Net realized gains on investments

     61.6        52.2        18.0

Other-than-temporary impairment losses on investments:

      

Total other-than-temporary impairment losses on investments

     (10.4     (69.1     84.9

Portion of other-than-temporary impairment losses recognized in other comprehensive income

     7.2        38.4        (81.3 %) 
                  

Other-than-temporary impairment losses recognized in income

     (3.2     (30.7     89.6
                  

Total revenues

     14,598.2        15,425.1        (5.4 %) 

Expenses

      

Benefit expense

     11,204.7        11,552.8        (3.0 %) 

Selling, general and administrative expense

      

Selling expense

     400.7        420.6        (4.7 %) 

General and administrative expense

     1,689.3        1,839.7        (8.2 %) 
                  

Total selling, general and administrative expense

     2,090.0        2,260.3        (7.5 %) 

Cost of drugs

     —          112.7        (100.0 %) 

Interest expense

     106.3        110.6        (3.9 %) 

Amortization of other intangible assets

     60.4        66.0        (8.5 %) 

Impairment of other intangible assets

     —          205.5        (100.0 %) 
                  

Total expenses

     13,461.4        14,307.9        (5.9 %) 

Income before income taxes

     1,136.8        1,117.2        1.8

Income tax expense

     397.7        387.0        2.8
                  

Net income

   $ 739.1      $ 730.2        1.2
                  

Net income per diluted share

   $ 1.84      $ 1.53        20.3
                  

Diluted shares

     402.2        476.8        (15.6 %) 

Benefit expense as a percentage of premiums

     83.8     82.1     170 bp 

Selling, general and administrative expense as a percentage of total operating revenue

     14.6     14.9     (30 )bp 

Income before income tax expense as a percentage of total revenues

     7.8     7.2     60 bp 

 

9


 

WellPoint, Inc.

Consolidated Statements of Income

(Unaudited)

 

     Nine Months Ended
September 30
    Change  
(In millions, except per share data)    2010     2009    

Revenues

      

Premiums

   $ 40,533.7      $ 42,397.2        (4.4 %) 

Administrative fees

     2,865.1        2,887.4        (0.8 %) 

Other revenue

     28.8        486.9        (94.1 %) 
                  

Total operating revenue

     43,427.6        45,771.5        (5.1 %) 

Net investment income

     608.8        599.4        1.6

Net realized gains on investments

     146.5        20.4        NM (1) 

Other-than-temporary impairment losses on investments:

      

Total other-than-temporary impairment losses on investments

     (53.2     (481.9     89.0

Portion of other-than-temporary impairment losses recognized in other comprehensive income

     24.2        72.2        (66.5 %) 
                  

Other-than-temporary impairment losses recognized in income

     (29.0     (409.7     92.9
                  

Total revenues

     44,153.9        45,981.6        (4.0 %) 

Expenses

      

Benefit expense

     33,571.1        35,127.1        (4.4 %) 

Selling, general and administrative expense

      

Selling expense

     1,206.2        1,273.8        (5.3 %) 

General and administrative expense

     5,265.9        5,421.3        (2.9 %) 
                  

Total selling, general and administrative expense

     6,472.1        6,695.1        (3.3 %) 

Cost of drugs

     —          346.4        (100.0 %) 

Interest expense

     305.9        343.7        (11.0 %) 

Amortization of other intangible assets

     182.0        200.5        (9.2 %) 

Impairment of other intangible assets

     21.1        205.5        (89.7 %) 
                  

Total expenses

     40,552.2        42,918.3        (5.5 %) 

Income before income taxes

     3,601.7        3,063.3        17.6

Income tax expense

     1,263.4        1,059.2        19.3
                  

Net income

   $ 2,338.3      $ 2,004.1        16.7
                  

Net income per diluted share

   $ 5.52      $ 4.12        34.0
                  

Diluted shares

     423.4        487.0        (13.1 %) 

Benefit expense as a percentage of premiums

     82.8     82.9     (10 )bp 

Selling, general and administrative expense as a percentage of total operating revenue

     14.9     14.6     30 bp 

Income before income tax expense as a percentage of total revenues

     8.2     6.7     150 bp 

 

(1)

“NM” = not meaningful

 

10


 

WellPoint, Inc.

Consolidated Balance Sheets

 

(In millions)    September 30,
2010
     December 31,
2009
 
     (Unaudited)         

Assets

     

Current assets:

     

Cash and cash equivalents

   $ 2,246.2       $ 4,816.1   

Investments available-for-sale, at fair value:

     

Fixed maturity securities

     16,733.9         15,696.9   

Equity securities

     1,072.9         1,010.7   

Other invested assets, current

     17.3         26.5   

Accrued investment income

     177.6         172.8   

Premium and self-funded receivables

     3,176.4         3,281.0   

Other receivables

     908.4         879.5   

Securities lending collateral

     893.6         394.8   

Deferred tax assets, net

     416.0         523.8   

Other current assets

     1,297.1         1,268.6   
                 

Total current assets

     26,939.4         28,070.7   

Long-term investments available-for-sale, at fair value:

     

Fixed maturity securities

     231.9         230.4   

Equity securities

     32.3         32.5   

Other invested assets, long-term

     845.1         775.3   

Property and equipment, net

     1,206.7         1,099.6   

Goodwill

     13,265.4         13,264.6   

Other intangible assets

     8,056.5         8,259.3   

Other noncurrent assets

     455.1         393.0   
                 

Total assets

   $ 51,032.4       $ 52,125.4   
                 

Liabilities and shareholders’ equity

     

Liabilities

     

Current liabilities:

     

Policy liabilities:

     

Medical claims payable

   $ 4,956.3       $ 5,450.5   

Reserves for future policy benefits

     57.9         62.6   

Other policyholder liabilities

     1,705.1         1,617.6   
                 

Total policy liabilities

     6,719.3         7,130.7   

Unearned income

     989.4         1,050.0   

Accounts payable and accrued expenses

     2,752.7         2,994.1   

Income taxes payable

     62.1         1,228.7   

Security trades pending payable

     264.0         37.6   

Securities lending payable

     894.9         396.6   

Short-term borrowings

     100.0           

Current portion of long-term debt

     706.5         60.8   

Other current liabilities

     1,652.6         1,775.2   
                 

Total current liabilities

     14,141.5         14,673.7   

Long-term debt, less current portion

     8,217.2         8,338.3   

Reserves for future policy benefits, noncurrent

     653.8         664.6   

Deferred tax liability, net

     2,621.6         2,470.4   

Other noncurrent liabilities

     1,036.6         1,115.1   
                 

Total liabilities

     26,670.7         27,262.1   

Shareholders’ equity

     

Common stock

     4.0         4.5   

Additional paid-in capital

     13,403.5         15,192.2   

Retained earnings

     10,581.8         9,598.5   

Accumulated other comprehensive income

     372.4         68.1   
                 

Total shareholders’ equity

     24,361.7         24,863.3   
                 

Total liabilities and shareholders’ equity

   $ 51,032.4       $ 52,125.4   
                 

 

11


 

WellPoint, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

     Nine Months Ended September 30  
(In millions)    2010     2009  

Operating activities

    

Net income

   $ 2,338.3      $ 2,004.1   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Net realized gains on investments

     (146.5     (20.4

Other-than-temporary impairment losses recognized in income

     29.0        409.7   

Loss on disposal of assets

     1.3        9.0   

Deferred income taxes

     111.0        (7.7

Amortization, net of accretion

     364.3        337.7   

Depreciation expense

     78.2        78.7   

Impairment of other intangible assets

     21.1        205.5   

Share-based compensation

     96.6        115.7   

Excess tax benefits from share-based compensation

     (25.1     (5.3

Changes in operating assets and liabilities, net of effect of business combinations:

    

Receivables, net

     (22.8     (127.4

Other invested assets

     8.9        (39.0

Other assets

     (89.9     9.4   

Policy liabilities

     (422.3     (492.7

Unearned income

     (60.6     10.3   

Accounts payable and accrued expenses

     (152.4     243.6   

Other liabilities

     (116.6     18.0   

Income taxes

     (1,143.9     255.7   

Other, net

     (38.9     4.3   
                

Net cash provided by operating activities

     829.7        3,009.2   

Investing activities

    

Purchases of fixed maturity securities

     (8,212.6     (5,331.1

Proceeds from sales and maturities of fixed maturity securities

     7,997.3        4,145.9   

Purchases of equity securities

     (191.9     (195.0

Proceeds from sales of equity securities

     157.1        453.3   

Purchases of other invested assets

     (67.9     (36.9

Proceeds from sales of other invested assets

     25.4        2.4   

Changes in securities lending collateral

     (498.3     142.3   

Purchases of subsidiaries, net of cash acquired

     (0.2     (66.3

Purchases of property and equipment

     (333.6     (272.3

Proceeds from sales of property and equipment

     6.0        0.4   

Other, net

     (50.2     (3.2
                

Net cash used in investing activities

     (1,168.9     (1,160.5

Financing activities

    

Net repayment of commercial paper borrowings

     (109.5     (356.6

Net proceeds from short-term borrowings

     100.0        2.0   

Proceeds from long-term borrowings

     1,088.5        990.3   

Repayment of long-term borrowings

     (480.0     (602.9

Changes in securities lending payable

     498.3        (142.3

Changes in bank overdrafts

     (123.0     (354.6

Repurchase and retirement of common stock

     (3,345.1     (1,811.4

Proceeds from exercise of employee stock options and employee stock purchase plan

     116.2        77.6   

Excess tax benefits from share-based compensation

     25.1        5.3   
                

Net cash used in financing activities

     (2,229.5     (2,192.6
                

Effects of foreign currency exchange rate changes on cash and cash equivalents

     (1.2     2.2   
                

Change in cash and cash equivalents

     (2,569.9     (341.7

Cash and cash equivalents at beginning of period

     4,816.1        2,183.9   
                

Cash and cash equivalents at end of period

   $ 2,246.2      $ 1,842.2   
                

 

12


 

WellPoint, Inc.

Reconciliation of Medical Claims Payable

 

     Nine Months Ended September 30     Years Ended December 31  
(In millions)    2010     2009     2009     2008     2007  
     (Unaudited)                    

Gross medical claims payable, beginning of period

   $ 5,450.5      $ 6,184.7      $ 6,184.7      $ 5,788.0      $ 5,290.3   

Ceded medical claims payable, beginning of period

     (29.9     (60.3     (60.3     (60.7     (51.0
                                        

Net medical claims payable, beginning of period

     5,420.6        6,124.4        6,124.4        5,727.3        5,239.3   

Business combinations and purchase adjustments

     —          2.8        2.8        —          15.2   

Net incurred medical claims:

          

Current year

     33,834.5        35,422.9        47,315.1        47,940.9        46,366.2   

Prior years (redundancies) 1

     (704.8     (751.9     (807.2     (263.2     (332.7
                                        

Total net incurred medical claims

     33,129.7        34,671.0        46,507.9        47,677.7        46,033.5   

Net payments attributable to:

          

Current year medical claims

     29,137.6        30,093.0        42,056.9        42,020.7        40,765.7   

Prior years medical claims

     4,486.9        5,007.3        5,157.6        5,259.9        4,795.0   
                                        

Total net payments

     33,624.5        35,100.3        47,214.5        47,280.6        45,560.7   

Net medical claims payable, end of period

     4,925.8        5,697.9        5,420.6        6,124.4        5,727.3   

Ceded medical claims, end of period

     30.5        65.3        29.9        60.3        60.7   
                                        

Gross medical claims payable, end of period

   $ 4,956.3      $ 5,763.2      $ 5,450.5      $ 6,184.7      $ 5,788.0   
                                        

Current year medical claims paid as a percent of current year net incurred medical claims

     86.1     85.0     88.9     87.7     87.9

Prior year redundancies in the current period as a percent of prior year net medical claims payables less prior year redundancies in the current period

     14.9     14.0     15.2     4.8     6.8

Prior year redundancies in the current period as a percent of prior year net incurred medical claims

     1.5     1.6     1.7     0.6     0.8

 

1

Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.

 

13


 

WellPoint, Inc.

GAAP Reconciliation

(Unaudited)

WellPoint, Inc. has referenced “Adjusted Net Income” and “Adjusted Net Income Per Share,” non-GAAP financial measures, in this document. These non-GAAP financial measures are not intended to be alternatives to any measure calculated in accordance with GAAP. Rather, these non-GAAP financial measures are intended to aid investors when comparing WellPoint, Inc.’s financial results among periods. A reconciliation of these measures to the most directly comparable measures calculated in accordance with GAAP is presented below.

 

      Three Months Ended        
(In millions, except per share data)    September 30, 2010     September 30, 2009     Change  

Net income

   $ 739.1      $ 730.2        1.2

Add (net of tax):

      

Impairment of other intangible assets, net of $71.1 million of tax benefits

     —          134.4     

Subtract (net of tax):

      

Net investment gains, net of tax expense totaling $20.5 million and $7.4 million, respectively

     (37.9     (14.1  
                  

Net adjustment items

     (37.9     120.3     
                  

Adjusted net income

   $ 701.2      $ 850.5        (17.6 %) 
                  

Diluted shares

     402.2        476.8        (15.6 %) 

Net income per diluted share

   $ 1.84      $ 1.53        20.3

Adjusted net income per diluted share

   $ 1.74      $ 1.78        (2.2 %) 
     Nine Months Ended        
     September 30, 2010     September 30, 2009     Change  

Net income

   $ 2,338.3      $ 2,004.1        16.7

Add (net of tax):

      

Net investment losses, net of $137.0 million of tax benefits

     —          252.3     

Impairment of other intangible assets, net of tax benefits totaling $7.4 million and $71.1 million, respectively

     13.7        134.4     

Subtract (net of tax):

      

Net investment gains, net of $41.4 million of tax expense

     (76.1     —       
                  

Net adjustment items

     (62.4     386.7     
                  

Adjusted net income

   $ 2,275.9      $ 2,390.8        (4.8 %) 
                  

Diluted shares

     423.4        487.0        (13.1 %) 

Net income per diluted share

   $ 5.52      $ 4.12        34.0

Adjusted net income per diluted share

   $ 5.38      $ 4.91        9.6

 

14


 

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES

LITIGATION REFORM ACT OF 1995

WellPoint and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this press release, in presentations, in filings with the Securities and Exchange Commission, or SEC, in reports to shareholders and in meetings with analysts and investors. The projections referenced in this press release are forward-looking and they are intended to be covered by the safe harbor for “forward-looking statements” provided by PSLRA. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)”, “intend”, “estimate”, “project” and similar expressions are intended to identify forward-looking statements, which generally are not historical in nature. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in our public filings with the SEC; increased government participation in, or regulation or taxation of health benefits and managed care operations, including, but not limited to, the impact of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; trends in health care costs and utilization rates; our ability to secure sufficient premium rates including regulatory approval for and implementation of such rates; our ability to contract with providers consistent with past practice; competitor pricing below market trends of increasing costs; reduced enrollment, as well as a negative change in our health care product mix; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon and funding risks with respect to revenue received from participation therein; a downgrade in our financial strength ratings; litigation and investigations targeted at health benefits companies and our ability to resolve litigation and investigations within estimates; our ability to meet expectations regarding repurchases of shares of our common stock; decreased revenues, increased operating costs and potential customer and supplier losses and business disruptions that may be greater than expected following the close of the Express Scripts transaction; events that result in negative publicity for us or the health benefits industry; failure to effectively maintain and modernize our information systems and e-business organization and to maintain good relationships with third party vendors for information system resources; events that may negatively affect our license with the Blue Cross and Blue Shield Association; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; intense competition to attract and retain employees; unauthorized disclosure of member sensitive or confidential information; changes in the economic and market conditions, as well as regulations that may negatively affect our investment portfolios and liquidity; possible restrictions in the payment of dividends by our subsidiaries and increases in required minimum levels of capital and the potential negative effect from our substantial amount of outstanding indebtedness; general risks associated with mergers and acquisitions; various laws and our governing documents may prevent or discourage takeovers and business combinations; future public health epidemics and catastrophes; and general economic downturns. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by federal securities law, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in our SEC reports.

 

15

GRAPHIC 3 g115639image_pg7.jpg GRAPHIC begin 644 g115639image_pg7.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`, M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8 M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\? M'Q\?'Q\?'Q\?_\``$0@`'@"6`P$1``(1`0,1`?_$`',```("`P$!```````` M```````%!`8!`P<""`$!`0````````````````````$0``$$`0,"!`0%`P4! M``````(!`P0%!@`1$B$3,2(4!X$R(Q5!46&A%D(T"'%27GV]^*IR^;IH'G M)/WVT!R300';^J:N0IG'N-@Y'.8+2HNW8;)`(^7AT)=`/9!4-)`59(F%FZC$ M%QOZ@..*!&B(0[CMQ!>N@8(J+H$N5YCC^*UBV5W(5B-S1L$`"=<,R\!!L$(S M7_BF@WX[DE/D5-'N*E[OP)**K3BB0%Y5XJA"2(0DBILJ*F^@9*8IUT!R';?? MI^>@UR9+,:.[(>+BTR!..+MOL()R7HGZ)H%CF6T+>.M9$4G_`,AYMMUN0@DN MX/*@AY43?JI)H&_)-]M!!J[RLM/6>B=[OH)!Q)714XO-[.@A3+2PR+(*NT!P(3:L1&WA^LXRVXK8J3A`B(._S$JZ"A1_=[,G\8NBK9T*VGUF00ZFNM1:0 M69<:80\",!)10O-LJCH)>09YF-1U-DW0UYX7_7YET1%1-!)Q-IHK+% M`==0&UP%\"=1"78>;:*:(B>&W7;QT&/;N19N8-[8,2HB,,1+5MJ#+%U#&8PD M.5Q?$-D<;W_VN(BZ"9B4S,8VZ9Y+W`QQUV/P;9-AUN,TL@U&,3@+]73SSJ_=;(7X-7!R`I M57#&1$E/18SD66VCGIRY35;`V707S=HB(=NJ>&@O>*R!]+@HS8RP15 M%!W&.(EX[;EX[[Z"LXI*L0I*NK"$RZD;,>5MD!.-H])>]<2@"1RVE"?44+N@ M(\4Z*J+HIC='+8494-H9DV/[DN.1J\2[9R#[)(K0.'LV![+ON9(/ZZ(VS'Y3 ML/*)]S&CQ[<,LKI,2G><$V7'A8;4(;SZIV1(V.6YJO;0OZMM!;8MSGI0[^RQ M>@J&YH^E;I:/O0UD$&Z>I=E/Q'NVB=?(//\`#X:#JL=25H5-$0U%.8IX(OX_ (OH-F@-!__]D_ ` end GRAPHIC 4 g115639press.jpg GRAPHIC begin 644 g115639press.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`, M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8 M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\? M'Q\?'Q\?'Q\?_\``$0@`>@+&`P$1``(1`0,1`?_$`,```0`"`P$!`0`````` M```````&!P0%"`,!`@$!``,!`0$```````````````,$!0(!!A````4!!`4( M!@4(!P4)`0````$"`P0%$1(&!S&1TE05(4$B,A.451A183,4-0AQ@7(T-K%" M4F*"(Q8WH<&R0V.S)(-TA'47T?&2HE-S148G.!$!``$"`P<"`P8$!0,%```` M``$"`Q&A4C$28A,$%!4A,D%Q!5%A@;$B,Y%"(P;PP=&"0^&#-/%RPB06_]H` M#`,!``(1`Q$`/P#GR!`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`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`Y%E@@ MZCJ.7AZ8XIK%C?Q]4@/)_+6:Y.5K^/>(DA+$E<;A_96F=Q5E[M+ MW/\`9%>KJ,+FY@GCI\:-[%"!95@BM41>DR+6=@/8776/E[PO0ULMUK,"'3GG MT$XVU(82A1I/G*\Z0H4]955LIQ7:NDIC;4K['>$L/8=>BHHV)HV(TODHW5QD MDGLC+02K%+TBS9N55;:=U!=MTT[)Q143(%O'\NM73EW_`!>NI79*8AS5TGL# MO$DK3N]I>TW>7JBCWT;^[@O3T<[N.*H"T"\HMUA#"M4Q7B&+0J623ERC,R-9 MV)2A!6K4?V2Y1'=N113C*2U;FN<(6DCY<*?(F/4F!C6#*Q!'0:G:42")9&1: M#,EF9?\`A%/OIPQFGT6^SC'#'U5!6:1/HU5E4NH-]E,AN&T^WIL47_;I%ZBN M*HQA3KHFF<)2S*G+(L?3ZG%55$TI%-CIDK>4UVI&E2C2?YR++++1#U%_EQ'I MCBEL6.9\4B=R>RY;2O\`_3Z::T6]'LTZ2YN1TQ%W->B4O;T:H50^VAM]UM"R M<0A:DI<+0HDF9$HOITBY&Q3F,)?@>O`````````````````````````````` M``&-*^\P_MK_`,LQ#<]U'SG\DMOVU?*/S*;\/C?8(.G_`&Z?D7_W*OFR1,B` M`````````````````````````````!+7[(S[5ROE[L4X_>OW**=_&95/ MGEC"DXKQ\[4*2HW($>.U#:>,K+_9&HS47J.]R"[TEN:*,)4NJKBJKT;;Y8_Y MLQ?]RE_V4CGKOVW?1>]/,-Y48,7FPW56L:Q)U0CS534T:.24O]HT=ZZHR<4= MB?SNB*M=^KE8;OI]JS39IYF.*HL] M(O=)3$6X4^JJQKE,OE6_F%(_W18K_4/;";H=LO.H1_E@]_E]M(Q`4CMW>VND M=WM+YW[.AHO:![3-_#^5U5RL?7')4#_8]N[V%IL7U=B:NMAC_!=(3E6 MY6\$XEF2L)QG$J?H\ESM&TFXLBZ)6)-)I6HN0>V;L\S"NF-[[7EZW&YC3/HH MH:3-````7-\JZ4KQS6$*5<2JD.D:CT$1O-\HH?4/9'S7NA]W^/N2W+?*K!T3 M,9-9@XSBUJH05O2FZ5$)*'+UAI._8M=J2O>@07K]4V\)IPA/:LTQ7CCBH_,: MJ2:ICNN3)+78.KF.I[&RPT$E1D25>LN<:'3TQ%$*'453-R M]S/M+NF[SV?4*GU#X+?1;):-^/\`+![NY[O(Q!V]U797B.R_8=VWH:+1)$]1 MPN9Y/WY*H%U07C1O_P"5I_\`S-[^V0SJ_P#R(:5'[,J.&BS7U'71]I/Y2![# MJ/.UK)U=4I9XW=JB)WNJ?=R@$9HN?K=%7*,?I>9Z[F#6O[GIO.>L;HP,BLI+ M!2YBZ/V*;YSRL=[>\J]9R%T;MT:=K?P_7M9U[=Q_2^8$PXYB3%]*HR4&MN5( M0E\BYFB/IJ^H@OW-RB9+%&]5$.O6W\0?]3%T)=*D'A%RDICE-[(_=^V;O6I- M>CE2HB(8F$;F./ZL6OC.]A\,'(&.,/NX>Q=5J.Y:9Q)*TI4966I4=])E]2AM MV:]ZB)9%^C=JF&XR?K-9H>.H=7I-*>K+T9#B784NSD&AT]<541,1@ MH=11--7JL;Y6/=^+XL]YO%'X6GMKG6N7U7K/78*WU#9'S6>A^+35>/\`+44: M<<-^O'4KKONY.$?9]O8=R]T.K?TCNB;_`*;,'E?*]=N/X*G3;=*]UK.6STBZ MHR^@\````````````````````````````````8TK[S#^VO\`RS$-SW4?.?R2 MV_;5\H_,IOP^-]@@Z?\`;I^1?_Q52:\I@Y*:9)1)..2KAKN6]$E&1V:A'=HWJ9C[4EJO=JQ9>8 M6+6\78LFU]$0X:99D91U+)PTV%9UB)-NH!\ M7-8@@0=1:YE.">Q=W)Q?*#CI%)S$3C`H1 MN(3)7).$2R2HR6=MV_9_4/*[&-OPIQQ1K6HY"+34H[3/JWN MZT_<4:57UZ=3Y]9ES*="338+[AKCP$'>2RG]`CYQ;HIF(B)G&5.Y5$U8QZ)E MEKF],P=!ETB93VZQ09IWWH#IDFQ9E89I49'R&1>@07^EBN<8G"4]CJ9HC"?6 M&\J.>]*BT";2,%858PUQ%)HE2$K2XHTJ*Q5EU*+.0Q''1S-4375BDJZN(C"F M,%1?T^LQ>4L5G8-SJ;I6%BPKB6AM8CH;9VQV'%$A2",[;+QDJWET"G=Z3&K> MIG"5RUU6%.%48OSCG.=-=PPG"M`HC6'L/WB4]$;42S7=.\17B)/);RZ`L]+N MU;U4XR\N]3C3NQ&$*S%Q3````33*K,1K`E9&&."QT][H[195H7A7<_,OL0+8>KV7R: ME(CMDTVZ])09DDN8OW8SZ.CKIV58+]754SMA7N/L58-KWN7\-X6;PU[N:SDF MVX3G;7B*Z1V$FR[8+-FW53CO58J]ZY35LC![94X_IV!<1+KDJE*JCY-*:C)0 MZ379W^1:K32NVTAYU%F;D81.!T]Z*)QF&Q1GUF1_$B*JY6))P4RB?52DJ03) MM$JWL>KU3+D'/9T;N&'K]KONZM['X-7FICR#CC$B:Y&IBJ8LV4M2&E.$[?6D MSZ=I)39R<@ZZ>S-NG#'%QU%V*YQ:K!>,*MA'$,>N4M1>\,6I4VLK4K;5R*29 M>LAW=M173A+BU=FB<86B7S`8-14CKC6`8Z<1&5O$NU1USTJNW/ZQ3[*K##>] M%SNZ<<F5NIK)4N8N\LDE8E)$5B4I+T$1"[;MQ13A"EN&"7I[\4 M)"K-7)Q1FH\KHYJ49F9^\(TG^P(NWNZTW<4:53RW6G9;[K+9,LN.+6TR7*2$ M*49I01_JER"[$>BC5.,O(>O````````````````````````````````&-*^\ MP_MK_P`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````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````!^'GF6&U.O+2VVDK5+49$1%ZS,)EU33-4X1 M&,HK6,UL!4JWWBK,NJ3I1'/ME%]2+1%5?HCXM7I_H75W=E$Q\_3\V=A/'>&< M5,N.4:5VQLG8XTM)MN%;SFA5AV#VW=IKV(.N^EW^EF(NQAC^,-^)&>`````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````\6ID5V0]&;<2I^/=[9 MLCZ2;Q6IM+UD/,7=5NJ*8JF/2=CQGUJCT])JGS6(I%I-YQ*/[1D$U1&U):Z: MY<]E,U?*$"Q#G[@:E$M$9QRI2$Z$,E8@_P#:*Z(KU]51#>Z3^U>JN^M6%$?? M_HA;^;&:6+%]AA6CJB17#L1*))J47TNG:V6H0S?N5^V&U1]"Z#I(QOU[U7V? M]-K\_P#1G,&KVS\6XB**G2^E3BEG=^TA26RU!V]<^M4O?_T726OT=/:WOL]/ M\2_#F'<@\,6E4IRZT^7*I*3[8K?1^Y(K/K,>;EFG;ZNHZOZMU/LIBW'\/S8= M-S2RRH%>14L.X>DQ#2@V7S9=2E#C:C(^DA=X[2L'E-^W3.-,)KWT3K>HM31> MNTU?&,8V3\X7[A^NT^O4>+5H"[\64@EHMTE;I2HN8R%^BJ*HQA\!U?2UV+DV MZ_=2V(Z5@``````````````````````````````````````````````````` M```````````````````````````````````````````````````````5YFCE MJK$1IJ\&I.4N=$:43SC=^ZXTGI=(FS2HU%9R"O>L[WK$X/HOHGUGM_Z==$5T MU3Z;/2?Q5G3F3/17LA<)D1P8*JQ4&N5+BTJ.VS]95C?]`]WK-&SU5YZ7ZKU M?OJY=$_X^;ZK-C,;$)^Z8.H'N,1SD;?0W::3_P#<(NR+4/>?75[8(^A='T_Z MNIN;U7V3/^6T+)S,:MF<[%N("B(TOI6Z:SN_2A26RU!V]=7K5)_^AZ.S^CI[ M>]]GI_KZBJ)D)A&TI\DZ[+25XB(S>*]Z+6;$E]9ANVJ-OJ=S]6ZOV1RJ?X?F M_)YS0W4^Z80P:V[=Y"O-D];]*6RO:S'GQ_;M4?JZF_,?CA^;888S$Q M[2)+953"A0:"^^;DMQAEY!M&Z?278HS(BM'5%VN-M/H@ZWZ3TEZ)Y=[>NQ'I MC,>N'P7BE1*22DG:1\I&0O/A9@`````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````R(R,C*TCTD`HS,;)W`M,E+K\R3+A4V4_P#ZLHZ4*0P:[3OV M&E2KJEBGUG8^Z^C_`-P=5=IY5,4U5TT^F/\`-]SQI=9^7_"S"5QT M'4IJ.4G76EK6H_7:1-EJ"*K-'WN[_3_5^JG"9W*?NF/_`%?)F?-7J#:H6"\. MJ0I71)PD=H:3/\XD,E87UCR>JF?2F"W_`&O;MSO=3=_R_-J&/D+ULMFG\@XY-RO:N5?6OIW2QNVJ<9C[(_SE.\(_+WA>E+*16%<6 MD_\`IJ*XR1^DDETM9BQ;Z2F-OJPNO_NR_=C"U_3C-9D&DTR`A*(41J.E)6$3 M:$I_I(A9BF(V/F;O47+DXU53+)6A"T&A:24A7(I*BM(_J,>HHF8]8?2(B(B( MK"+00/`````````````````````````````````````````````````````` M``````````````````````````````````````````````````````&/4:=! MJ4)V#.93(B/INNLK*U*B]8\F(F,)26;U5NJ*Z)PJA%8F3V6\5XGF:(S?([4F MI3BB+ZC58(:>GHCX-:Y_;*\PNPKI$HB*U*O7RC3Z&S;N_IJCUA7O5U4^L))2 M)6,ZWEC$KM)K).5J4PQ(B3>NVIY#TB*N+=%V::H_3L=Q,S3C& MU"NZ:W9IB8C'% M':N553ZK%S)A@JGB:7[]/%$80] MIQPQE%VOF/RX7-53S.H%44F:502@R%/$9%:?[LDWN3Z!8\;=PQ],/G#F+U+Y M4/F-P#3FC=GLU.(UH2N1`D-),_01K20\I^G7)](P_B:T6+'357?2G:XJKBG:U6%L[L&8JJ34"A(FRU.*NG(**\EE!V6]-PTW4_68 MDN]#7;C&K"/Q>1=B9]%@"FD8=7B39<);,*8J#(/E0^A*56'ZR41E8.J)B)]8 MQ>3#G"E9O9H5'-!.!'JA'8_USL)22B/3)*8FI0F)#,99V-^\M+9 M6HOTB0LB.PQ6NVIHG"7=-6*-XOSIP9A"HN0:][W%6FRX\45U;*[=!(<)-TS^ ML36>BKN1C3A_%S50I12HC4DD*;)Y)+)#A&E1$?,HCT&*=483@DB59I^8_+E3LIM)S MEE"6M$IQJ&\XALVS,E7E)29$7(+WCKOIL]?O1\Z'X/YELLSBJF-+G.PT'8N4 MF$_V23TV&N[=M'OC+N.'IC\SG4K%P_7(-=HT2KP#-4.:V3K"E%=,TF=G*1_0 M*5RW-%4TSMA)$XQBV`X>@``````````````````````````````````````` M````````````````````````````````````(3G-A,L49=U:G)1?DMM^\Q$D M5IF\QTT%]9E8+717>7=B4=VG>IF%<_+%CR.G`54I=3=NGALUO+,SY$1;#/\` M\JD*%WZGT\\R)C^;\T5BO],X_!`L*S:E@7/*G3ZFTF+$Q.2G/=V[20EJ8X:& MC/[)E>^L7+M,7;$Q&VG_`"14SNUX_:Z#QDTFOXEHF&BL7$:<*JU0BTDVPJ]& M^DEO(L,8UF=RF:_PC_-:J]9B$V(B(K"Y"+00JI',4BHPZ5\V+\V02R90AR_V M+:W5F:H9$70;)2CU#=BF:NCB(_QZJ%H@N+E/S6# M:<-3AFVDVFW4DM-T^4E6"ER*K-$7,?7'X)=Z*YP6=3(+=/IL2`VHU-Q&6V$* M5I-+:201G]1"C55C,S]J:(PA1OS@I2>":09D5I3E6'SE^Y4-7Z/[Y^2OU.R/ MFN+!3:&\'4-*$DA)0(QDE)$1[IY#Y?[U`M]#^]2CO>V4?^5M""RB@K))$MNG>Z7# MAAGQ.%U8V>-=JN8T2!A#"-&G2;TE,B3.D1GHS2#21I)-KR4AHBW8FY_,K M79FJO!TW3J=!IL%F#!91'B1T$AEELB2E*2*PN0AA5535.,[5N(PTWT$/$R:2Z9)L)5XG.6T;/T_^K:JHJV0JWOTU1,.CXSZ7 MXS3Z>JZA*R^A16C%F,)6XIHKIG[D]6$S$K`.VSD MT\PII5=5C!]/PME#B"G14(4X4":X_)))$MQ;A+69J/2?6L%VB]-R]3,_;"&J MC=HE$/E8@0I^54R)-91(C/374.-.))23(VD$?(8L_5*IB[$Q]CFQ&-*WL*4% M-`H$2D(<[5$0EI0JRSHJ<4I)?LDJP9MVYOU35]J:F,(P;81N@``````````` M```````````````````````````````````````````````````````````` M`````RMY#T`.4Z+@2L4S/ZIX5@VLT2I&J1,29&:7*>?34A7-TE&I)#Z"Y?BK MIXKGW1^:E%']3"$R^:W"*7<)4W$,)'9NT1U+2U(+I]BY8A'*7,A7**WTJ]^N M:9_F2=13Z8PGF4-#JK5"+$=?<-W$%<;:=DVZ&64()+3*/U;"O?29BIUE<;V[ M3[:4EJGTQGXIZI24I-2C)*4E::CY"(B%-*YABURC%\V;DPY\=,1*74*DFZ@F MKQPR*R^9W=/)I&[515V>&'K_`-53'^IBNS$&*:J8G%FY?XAJ&)*'Q^0U[O$J*SWDG8M;C9_H(+H^LQ[?Z? ME4Q%7NDHKWI]-C!SZG0H^5>(&WY#;3CL_7& M&.QWOXSA":R),>.TIV0ZAEI/*IQQ1)27TF=A"K$3.Q(XSPW6:4GYERGJF,I@ MJK4HRE&XDFS2HG$D=^V[8=ND?37:)[7##UW84*9_J8_!V:R\R\V3C*TN-JZJ MT&2DG]!D/F9C!??L>#FK/3!6(J!F3`S*I4-4VFL+8A?M`Q?ARO4AFK4V>R]#>03E[M$D:+2Y265 MO1,NU-=6VK9"M<_75A#I!EI+++;2"L2VDDI+U$5@Q)G%;< MU?-S4Z1.9;DNO,H3' M-:3=,C5R]"V]99SV"[]/M557(G!'=F,$GJE$PQCO!ITM]UJ;`DLI)+["T.=F MN[T5I4DS(E),045UVJ\=DNIB*HP45E5%Q7A3-RGY>UA7;4^G>^RJ8\=ZPVW& MR(E-V_FG=T>FT:O5[ERS-RG;.&*O;B8JPET\,);1/-:="BY=XA]Y?;8[2GR$ M-]HM*+RC;,B25IE:9BSTE,S=IP^U'=]LJV^4JHP"R[E,>\-^\-S7%K8)1&X2 M>S1RW+;U@N_5J9YD3]R/I]BU&,?X5?F1H;99&;*#2HM"C189F5B3M+08 MH3T]<1,X;$L5PD(@=@`````````````````````````````````````````` M``````````````````````````````````"#Q?YS5#V7P.-I]I]X=T>H6I_8 MC_W(X]_X/3./^7%9]G[$_;=0.C_<@N^U**+\'@Z/N[6C1U"%>O;+N-C[5_A4 MS1[!SK:.J>D*-L%6Q2$#V)_@KK_W_M=/YWZPUJ_^XKQ_M>&)-#/X*Y^OUM', M.K7_`''L_P"U>="^#0?8^P;^[>QZI>S_`%?0,BY[I3T[%4X]_%[WP#2GXSU^ MJ75]0T>F]G\WX(*]OP:VL?"G/P7S:?9Z>824;?\`D)_VK$RI_"Z?AOM%?"/N M_P#WBCU?O^/XI+>QILW?;P?A?45\7]EUBT>L2]%\=OX/+B-M_WX?@EN8/X9D^Q_P") M]E^WZA5Z;WNKFQ4ROA?_`-(ZI=7KZ2T>L:4>[_D13_M6_@C\.Q^II5[+J:?S M?4,SJ/?*>C8WPA=/*9]T>]GU%>V]GH_/_5](]IVCBG,O\:53VFE/X8^&_P"U M_6_3'U/3>R/_`);5&=LNH,F?P5#^%^S1\)T:/[__`!/2,'K?W)V_BM6MB=GH M%-(I>L?'ZE^%?:G\7^\_7ZAJT>V/?^"O\9V)UEA^'#^Y^V7\/^[\W4]0I]5[ M_C^*2UL1+&?XJE?AO07QOVNC\S^L6;'L_G_!Q5[O@DN5OPV5\.]J?PG[K^P( M.JVQM_':[MM)BS^>^"?9?S^;\7%'N^#)@=>- M]P^^IZWMO;?E]`\G\=CJ%H#/2@`````````````````````````````````` $``#_V3\_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----